Status:
COMPLETED
Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors
Lead Sponsor:
Uppsala University
Collaborating Sponsors:
Swedish Parkinson's Disease Foundation
Swedish Society for Medical Research
Conditions:
Parkinson Disease
Eligibility:
All Genders
30-90 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether oral intake of COMT inhibitors affects the smooth plasma levodopa levels achieved by intestinal levodopa/carbidopa infusion in advanced Parkinson's di...
Detailed Description
The aim is to measure variability in plasma levodopa levels during the following three treatments: Day 1: Duodopa in individually optimised dose Day 2: 80% of optimised Duodopa dose + two tablets of ...
Eligibility Criteria
Inclusion
- Parkinson's disease
- Duodopa treatment ongoing
- Hoehn \& Yahr stage 3-5 at worst
Exclusion
- Ongoing treatment with COMT inhibitors
- Dementia
- Psychosis
- Treatment with typical neuroleptics
- Contraindications for entacapone or tolcapone
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00906828
Start Date
October 1 2008
End Date
November 1 2009
Last Update
January 18 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uppsala University Hospital
Uppsala, Sweden, 75646